Literature DB >> 12091876

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Haidong Dong1, Scott E Strome, Diva R Salomao, Hideto Tamura, Fumiya Hirano, Dallas B Flies, Patrick C Roche, Jun Lu, Gefeng Zhu, Koji Tamada, Vanda A Lennon, Esteban Celis, Lieping Chen.   

Abstract

B7-H1, a recently described member of the B7 family of costimulatory molecules, is thought to be involved in the regulation of cellular and humoral immune responses through the PD-1 receptor on activated T and B cells. We report here that, except for cells of the macrophage lineage, normal human tissues do not express B7-H1. In contrast, B7-H1 is abundant in human carcinomas of lung, ovary and colon and in melanomas. The pro-inflammatory cytokine interferon-gamma upregulates B7-H1 on the surface of tumor cell lines. Cancer cell-associated B7-H1 increases apoptosis of antigen-specific human T-cell clones in vitro, and the apoptotic effect of B7-H1 is mediated largely by one or more receptors other than PD-1. In addition, expression of B7-H1 on mouse P815 tumor increases apoptosis of activated tumor-reactive T cells and promotes the growth of highly immunogenic B7-1(+) tumors in vivo. These findings have implications for the design of T cell-based cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091876     DOI: 10.1038/nm730

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  1859 in total

1.  Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

Authors:  Qifeng Zhou; Haiyan Xiao; Yanjun Liu; Yibing Peng; Yuan Hong; Hideo Yagita; Phillip Chandler; David H Munn; Andrew Mellor; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.

Authors:  David A Sallman; Amy F McLemore; Amy L Aldrich; Rami S Komrokji; Kathy L McGraw; Abhishek Dhawan; Susan Geyer; Hsin-An Hou; Erika A Eksioglu; Amy Sullivan; Sarah Warren; Kyle J MacBeth; Manja Meggendorfer; Torsten Haferlach; Steffen Boettcher; Benjamin L Ebert; Najla H Al Ali; Jeffrey E Lancet; John L Cleveland; Eric Padron; Alan F List
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

Review 3.  Melanoma in immunosuppressed patients.

Authors:  Agnieszka W Kubica; Jerry D Brewer
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

4.  In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.

Authors:  Robert T Manguso; Hans W Pope; Margaret D Zimmer; Flavian D Brown; Kathleen B Yates; Brian C Miller; Natalie B Collins; Kevin Bi; Martin W LaFleur; Vikram R Juneja; Sarah A Weiss; Jennifer Lo; David E Fisher; Diana Miao; Eliezer Van Allen; David E Root; Arlene H Sharpe; John G Doench; W Nicholas Haining
Journal:  Nature       Date:  2017-07-19       Impact factor: 49.962

5.  Adaptive resistance: a tumor strategy to evade immune attack.

Authors:  Sheng Yao; Lieping Chen
Journal:  Eur J Immunol       Date:  2013-02-04       Impact factor: 5.532

Review 6.  Immunomodulation in the treatment of haematological malignancies.

Authors:  Michela Cesco-Gaspere; Emma Morris; Hans J Stauss
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

Review 7.  Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.

Authors:  Samaresh Sau; Hashem O Alsaab; Ketki Bhise; Rami Alzhrani; Ghazal Nabil; Arun K Iyer
Journal:  J Control Release       Date:  2018-01-31       Impact factor: 9.776

Review 8.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors:  Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2020-02-17       Impact factor: 66.675

Review 9.  Immunobiology of hepatocarcinogenesis: Ways to go or almost there?

Authors:  Pavan Patel; Steven E Schutzer; Nikolaos Pyrsopoulos
Journal:  World J Gastrointest Pathophysiol       Date:  2016-08-15

Review 10.  Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Authors:  Maria G Castro; Marianela Candolfi; Thomas J Wilson; Alexandra Calinescu; Christopher Paran; Neha Kamran; Carl Koschmann; Mariela A Moreno-Ayala; Hikmat Assi; Pedro R Lowenstein
Journal:  Expert Opin Biol Ther       Date:  2014-04-29       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.